317 related articles for article (PubMed ID: 27190098)
21. Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review.
Durand C; Eldoma M; Marshall DA; Bansback N; Hazlewood GS
J Rheumatol; 2020 Feb; 47(2):176-187. PubMed ID: 30988125
[TBL] [Abstract][Full Text] [Related]
22. Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment.
Hiligsmann M; Dellaert BG; Dirksen CD; van der Weijden T; Goemaere S; Reginster JY; Watson V; Boonen A
Arthritis Res Ther; 2014 Jan; 16(1):R36. PubMed ID: 24479410
[TBL] [Abstract][Full Text] [Related]
23. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
Tatangelo M; Tomlinson G; Paterson JM; Ahluwalia V; Kopp A; Gomes T; Bansback N; Bombardier C
JAMA Netw Open; 2019 Dec; 2(12):e1917053. PubMed ID: 31808927
[TBL] [Abstract][Full Text] [Related]
24. Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective.
Husni ME; Betts KA; Griffith J; Song Y; Ganguli A
Rheumatol Int; 2017 Sep; 37(9):1423-1434. PubMed ID: 28623526
[TBL] [Abstract][Full Text] [Related]
25. A maximum difference scaling survey of barriers to intensive combination treatment strategies with glucocorticoids in early rheumatoid arthritis.
Meyfroidt S; Hulscher M; De Cock D; Van der Elst K; Joly J; Westhovens R; Verschueren P
Clin Rheumatol; 2015 May; 34(5):861-9. PubMed ID: 25711874
[TBL] [Abstract][Full Text] [Related]
26. What benefit-risk trade-offs are acceptable to rheumatoid arthritis patients during treatment selection? Evidence from a multicountry choice experiment.
Alten R; Nieto-Gonzalez JC; Jacques P; Montecucco C; Moots R; Radner H; Vonkeman HE; Heidenreich S; Whichello C; Krucien N; Van Beneden K
RMD Open; 2024 Jan; 10(1):. PubMed ID: 38199605
[TBL] [Abstract][Full Text] [Related]
27. Factors influencing rheumatologists' prescription of biological treatment in rheumatoid arthritis: an interview study.
Kalkan A; Roback K; Hallert E; Carlsson P
Implement Sci; 2014 Oct; 9():153. PubMed ID: 25304517
[TBL] [Abstract][Full Text] [Related]
28. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
29. Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.
van Overbeeke E; De Beleyr B; de Hoon J; Westhovens R; Huys I
BioDrugs; 2017 Oct; 31(5):447-459. PubMed ID: 28929342
[TBL] [Abstract][Full Text] [Related]
30. Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.
Weijers L; Baerwald C; Mennini FS; Rodríguez-Heredia JM; Bergman MJ; Choquette D; Herrmann KH; Attinà G; Nappi C; Merino SJ; Patel C; Mtibaa M; Foo J
Rheumatol Int; 2017 Jul; 37(7):1111-1123. PubMed ID: 28560470
[TBL] [Abstract][Full Text] [Related]
31. Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment.
van Hulst LT; Kievit W; van Bommel R; van Riel PL; Fraenkel L
Arthritis Care Res (Hoboken); 2011 Oct; 63(10):1407-14. PubMed ID: 21748861
[TBL] [Abstract][Full Text] [Related]
32. How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment.
Zartab S; Nikfar S; Jamshidi A; Toroski M; Varahrami V; Fatemi B; Kebriaeezadeh A
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):701-708. PubMed ID: 37218452
[TBL] [Abstract][Full Text] [Related]
33. Patient preferences do matter: a discrete choice experiment conducted with breast cancer patients in six European countries, with latent class analysis.
Stamuli E; Corry S; Foss P
Int J Technol Assess Health Care; 2023 Apr; 39(1):e21. PubMed ID: 37074007
[TBL] [Abstract][Full Text] [Related]
34. Are rheumatologists' treatment decisions influenced by patients' age?
Fraenkel L; Rabidou N; Dhar R
Rheumatology (Oxford); 2006 Dec; 45(12):1555-7. PubMed ID: 16690762
[TBL] [Abstract][Full Text] [Related]
35. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using "National Database of Health Insurance Claims and Specific Health Checkups of Japan".
Kamata Y; Minota S
Rheumatol Int; 2018 Apr; 38(4):663-668. PubMed ID: 29204683
[TBL] [Abstract][Full Text] [Related]
36. The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey.
Nikiphorou E; Galloway J; van Riel P; Yazici Y; Haugeberg G; Ostor A; Gogus F; Kauppi M; Sokka T;
Clin Exp Rheumatol; 2017; 35(3):477-483. PubMed ID: 28134086
[TBL] [Abstract][Full Text] [Related]
37. Relative importance of clinical outcomes and safety risks of antiseizure medication monotherapy for patients and physicians: Discrete choice experiment eliciting preferences in real-world study "VOTE".
Rosenow F; Winter Y; Leunikava I; Brunnert M; Joeres L; Sutphin J; Boeri M; Smith J; Villani F; Brandt C
Epilepsia; 2022 Feb; 63(2):451-462. PubMed ID: 34921391
[TBL] [Abstract][Full Text] [Related]
38. Physicians' stated trade-off preferences for chronic hepatitis B treatment outcomes in Germany, France, Spain, Turkey, and Italy.
Mohamed AF; Johnson FR; Hauber AB; Lescrauwaet B; Masterson A
Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):419-26. PubMed ID: 22330238
[TBL] [Abstract][Full Text] [Related]
39. A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.
Jobanputra P; Wilson J; Douglas K; Burls A
Rheumatology (Oxford); 2004 Feb; 43(2):206-10. PubMed ID: 12923291
[TBL] [Abstract][Full Text] [Related]
40. Can the General Public Be a Proxy for an "At-Risk" Group in a Patient Preference Study? A Disease Prevention Example in Rheumatoid Arthritis.
DiSantostefano RL; Simons G; Englbrecht M; Humphreys JH; Bruce IN; Bywall KS; Radawski C; Raza K; Falahee M; Veldwijk J
Med Decis Making; 2024 Feb; 44(2):189-202. PubMed ID: 38240281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
